The new facility will accelerate the biotech and pharmaceutical industry's development by manufacturing vaccines, cell and gene therapies, and protein-based therapies
Largest investment in active pharmaceutical ingredient manufacturing of synthetic medicines in U.S. history
EBITDA for the quarter stood at Rs 964 crore, representing an EBITDA margin of 24%
Investing considerably in production capacity for medical device packaging at its Rohrdorf and Halle sites in Germany
New solvent-free micronization technology expanded at the Darmstadt site in Germany
Reconfirms a relative bioavailability of 65 percent and significant savings when using DL-methionine
This acquisition enables MTD to open new, strategic markets
Ukrainian marketing approvals for paclitaxel, oxaliplatin and irinotecan mark a significant milestone in the company’s global expansion strategy
Christoph Funke's extensive career includes leadership roles at organizations such as Fresenius Kabi and Strides Pharma Science
Subscribe To Our Newsletter & Stay Updated
